05:05 PM EDT, 10/07/2024 (MT Newswires) -- Vincerx Pharma ( VINC ) said its VIP943 leukemia drug showed "promising safety and tolerability," achieving two complete responses to date in a phase 1 dose-escalation study

The VIP943 antibody-drug conjugate is being evaluated in relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and B-cell acute lymphoblastic leukemia, the company said Monday in a statement.

Another data update is expected by the end of the year, the company said.

In an update on VIP236 being evaluated in a first-in-human, phase 1 dose-escalation study as a monotherapy in patients with advanced solid tumors, the company said it intends to pursue a strategic partner to "champion its future development" in order to focus on VIP943.

Vincerx expects a cash runway into early 2025.

Shares of the company jumped 15% in after-hours activity.

Price: 0.8000, Change: +0.10, Percent Change: +14.61